

World Journal of *Gastrointestinal Endoscopy*

World J Gastrointest Endosc 2017 April 16; 9(4): 149-203



EDITORIAL

- 149 Laparoscopic surgery for complex and recurrent Crohn's disease
Sevim Y, Akyol C, Aytac E, Baca B, Bulut O, Remzi FH

MINIREVIEWS

- 153 Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?
Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S

ORIGINAL ARTICLE

Case Control Study

- 162 Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: A case control study
Garg H, Priyadarshini P, Aggarwal S, Agarwal S, Chaudhary R

Retrospective Cohort Study

- 171 Does serotonin reuptake inhibitor therapy increase the risk of post-sphincterotomy bleeding in patients undergoing endoscopic retrograde cholangio-pancreatography?
Yadav D, Vargo J, Lopez R, Chahal P

Retrospective Study

- 177 Does deep sedation with propofol affect adenoma detection rates in average risk screening colonoscopy exams?
Thirumurthi S, Raju GS, Pande M, Ruiz J, Carlson R, Hagan KB, Lee JH, Ross WA

- 183 Endoscopic balloon catheter dilatation *via* retrograde or static technique is safe and effective for cricopharyngeal dysfunction
Chandrasekhara V, Koh J, Lattimer L, Dunbar KB, Ravich WJ, Clarke JO

- 189 Analysis of the risk factors for severity in post endoscopic retrograde cholangiopancreatography pancreatitis: The indication of prophylactic treatments
Matsubara H, Urano F, Kinoshita Y, Okamura S, Kawashima H, Goto H, Hirooka Y

Observational Study

- 196 Endoscopic assessment and management of sporadic duodenal adenomas: The results of single centre multidisciplinary management
Rajkomar K, Kweon M, Khan I, Frankish P, Rodgers M, Koea JB

Contents

World Journal of Gastrointestinal Endoscopy
Volume 9 Number 4 April 16, 2017

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Endoscopy*, Andreas Sieg, MD, PhD, Assistant Professor, Department of Gastroenterology, Practice of Gastroenterology, 69115 Heidelberg, Germany

AIM AND SCOPE

World Journal of Gastrointestinal Endoscopy (*World J Gastrointest Endosc*, *WJGE*, online ISSN 1948-5190, DOI: 10.4253) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJGE covers topics concerning gastroscopy, intestinal endoscopy, colonoscopy, capsule endoscopy, laparoscopy, interventional diagnosis and therapy, as well as advances in technology. Emphasis is placed on the clinical practice of treating gastrointestinal diseases with or under endoscopy.

We encourage authors to submit their manuscripts to *WJGE*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great clinical significance.

INDEXING/ABSTRACTING

World Journal of Gastrointestinal Endoscopy is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, and PubMed Central.

FLYLEAF

I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Huan-Liang Wu*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Xin Kong*
Proofing Editorial Office Director: *Xiu-Xia Song*

NAME OF JOURNAL
World Journal of Gastrointestinal Endoscopy

ISSN
ISSN 1948-5190 (online)

LAUNCH DATE
October 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Atsushi Imagawa, PhD, Director, Doctor, Department of Gastroenterology, Mitoyo General Hospital, Kan-onji, Kagawa 769-1695, Japan

Juan Manuel Herrerias Gutierrez, PhD, Academic Fellow, Chief Doctor, Professor, Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen Macarena, Sevilla 41009, Sevilla, Spain

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com>

www.wjgnet.com/1948-5190/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Gastrointestinal Endoscopy
Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
8226 Regency Drive,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
April 16, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Retrospective Study

Endoscopic balloon catheter dilatation *via* retrograde or static technique is safe and effective for cricopharyngeal dysfunction

Vinay Chandrasekhara, Joyce Koh, Lakshmi Lattimer, Kerry B Dunbar, William J Ravich, John O Clarke

Vinay Chandrasekhara, Joyce Koh, Lakshmi Lattimer, Kerry B Dunbar, William J Ravich, John O Clarke, Division of Gastroenterology and Hepatology, Department of Internal Medicine, the Johns Hopkins Medical Institutions, Baltimore, MD 21287, United States

Vinay Chandrasekhara, Gastroenterology Division, Department of Internal Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104, United States

Vinay Chandrasekhara, Perelman Center for Advanced Medicine South Pavilion, Philadelphia, PA 19104, United States

Lakshmi Lattimer, Gastroenterology and Liver Diseases, Department of Internal Medicine, the George Washington University, Washington, DC 20037, United States

Kerry B Dunbar, Division of Gastroenterology and Hepatology, Department of Medicine, University of Texas Southwestern Medical School, Dallas VA Medical Center, Texas, TX 75216, United States

Author contributions: Chandrasekhara V and Clarke JO contributed to the study design, data analysis, manuscript preparation and revision; Koh J, Lattimer L and Dunbar KB contributed to data analysis, manuscript preparation and revision; Ravich WJ contributed to manuscript preparation and revision.

Institutional review board statement: This study was approved by the IRB at Johns Hopkins Hospital.

Informed consent statement: Patients were not required to give informed consent for this retrospective study because the study used anonymous clinical data.

Conflict-of-interest statement: None of the authors have any conflicts to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,

which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Vinay Chandrasekhara, MD, Perelman Center for Advanced Medicine South Pavilion, 3400 Civic Center Blvd, 4 South, Gastroenterology, Philadelphia, PA 19104, United States. chandrav@uphs.upenn.edu
Telephone: +1-215-3498222
Fax: +1-215-3495915

Received: July 27, 2016

Peer-review started: July 29, 2016

First decision: September 2, 2016

Revised: December 14, 2016

Accepted: January 11, 2017

Article in press: January 12, 2017

Published online: April 16, 2017

Abstract**AIM**

To evaluate the safety and efficacy of upper esophageal sphincter (UES) dilatation for cricopharyngeal (CP) dysfunction. To determine if: (1) indication for dilatation; or (2) technique of dilatation correlated with symptom improvement.

METHODS

All balloon dilatations performed at our institution from over a 3-year period were retrospectively analyzed for demographics, indication and dilatation site. All dilatations involving the UES underwent further review to determine efficacy, complications, and factors that predict success. Dilatation technique was separated

into static (stationary balloon distention) and retrograde (brusque pull-back of a fully distended balloon across the UES).

RESULTS

Four hundred and eighty-eight dilatations were reviewed. Thirty-one patients were identified who underwent UES dilatation. Median age was 63 years (range 27-81) and 55% of patients were male. Indications included dysphagia (28 patients), globus sensation with evidence of UES dysfunction (2 patients) and obstruction to echocardiography probe with cricopharyngeal (CP) bar (1 patient). There was evidence of concurrent oropharyngeal dysfunction in 16 patients (52%) and a small Zenker's diverticula (≤ 2 cm) in 7 patients (23%). Dilator size ranged from 15 mm to 20 mm. Of the 31 patients, 11 had dilatation of other esophageal segments concurrently with UES dilatation and 20 had UES dilatation alone. Follow-up was available for 24 patients for a median of 2.5 mo (interquartile range 1-10 mo), of whom 19 reported symptomatic improvement (79%). For patients undergoing UES dilatation alone, follow-up was available for 15 patients, 12 of whom reported improvement (80%). Nineteen patients underwent retrograde dilatation (84% response) while 5 patients had static dilatation (60% response); however, there was no significant difference in symptom improvement between the techniques ($P = 0.5$). Successful symptom resolution was also not significantly affected by dilator size, oropharyngeal dysfunction, Zenker's diverticulum, age or gender ($P > 0.05$). The only complication noted was uvular edema and a shallow ulcer after static dilatation in one patient, which resolved spontaneously and did not require hospital admission.

CONCLUSION

UES dilatation with a through-the-scope balloon by either static or retrograde technique is safe and effective for the treatment of dysphagia due to CP dysfunction. To our knowledge, this is the first study evaluating retrograde balloon dilatation of the UES.

Key words: Cricopharyngeal dysfunction; Cricopharyngeal bar; Dysphagia; Esophageal dilatation; Endoscopic balloon dilation

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Cricopharyngeal dysphagia can be treated with endoscopic balloon dilatation. In this series, a novel dilatation technique of pulling a fully inflated 15-20 mm balloon dilator in a retrograde manner across the upper esophageal sphincter was safe and effective for the treatment of cricopharyngeal dysphagia.

Chandrasekhara V, Koh J, Lattimer L, Dunbar KB, Ravich WJ, Clarke JO. Endoscopic balloon catheter dilatation *via* retrograde or static technique is safe and effective for cricopharyngeal dysfunction. *World J Gastrointest Endosc* 2017; 9(4): 183-188 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v9/i4/183.htm> DOI: <http://dx.doi.org/10.4253/wjge.v9.i4.183>

INTRODUCTION

The upper esophageal sphincter, comprised of the cricopharyngeus, or the cricopharyngeal (CP) muscle, inferior pharyngeal constrictor, and proximal cervical esophagus serves a pivotal role in the act of deglutition. The CP muscle normally remains in a contracted state and relaxes during swallowing prior to penetration of a food bolus into the cricopharyngeal region. Cricopharyngeal dysfunction (CPD) refers to incoordination of the cricopharyngeal muscle either due to a primary functional disorder or as a result of an underlying neurological or medical condition^[1]. Symptoms of CPD can range from a globus sensation to oropharyngeal dysphagia manifested by regurgitation, coughing, choking and recurrent aspiration.

The diagnosis of CPD can be difficult to make and often requires a meticulous history and physical examination. Videofluoroscopy is often helpful for the diagnosis of CPD with the typical appearance of a shelf in the posterior column of barium at the level of the cricoid cartilage, more commonly described as a cricopharyngeal bar^[2]. The incidence of CP bars is variable in the reported literature, ranging from 5% to 22% in patients who undergo videofluoroscopic swallow studies for dysphagia^[2-4]. CP bars are frequently detected in asymptomatic individuals and therefore other modalities such as esophageal manometry and upper endoscopy must be performed to exclude other etiologies of dysphagia.

Endoscopic treatment for CPD has not been well studied and remains controversial. Historically, management has relied upon surgical CP myotomy^[5-7]. Endoscopic dilatation poses an attractive option, given the risks associated with myotomy; however, published case series to date have included very small numbers of patients with varying dilatation techniques^[8-13]. The aim of our study was to determine the efficacy and safety of through-the-scope (TTS) balloon dilatation of the upper esophageal sphincter (UES) in patients with CPD and to compare the traditional static technique of sequential distention of the balloon with a brusque "pull-back" retrograde approach across the UES.

MATERIALS AND METHODS

The study was approved by the Johns Hopkins Medicine institutional review board. The medical records of all patients that underwent esophageal dilatation with a through-the-scope balloon dilator at the Johns Hopkins Hospital over a consecutive 3-year period were reviewed. Patients were included in the study cohort if they had CPD that was treated with TTS balloon dilatation of the UES, including those with a Zenker's diverticulum. Patients were excluded if they were under the age of 18 years old and if balloon dilatation of the UES was not performed. Patient demographics, prior radiographic data, procedural indications, test results, complications and follow-up clinical outcomes were recorded.

Data was analyzed using Stata version 9 (StataCorp,

Table 1 Patient demographics *n* (%)

Patients undergoing UES dilatation	<i>n</i> = 31
Age, yr, median (range)	63 (27-81)
Sex	
Male	17 (55)
Female	14 (45)
Indications	
Radiographic CP hypertrophy with dysphagia	22 (71)
Endoscopic UES tightness with dysphagia	3 (10)
Inclusion body myositis with dysphagia and prominent cricopharyngeus	3 (10)
Globus sensation with evidence of UES dysfunction	2 (6)
Obstruction to echocardiography probe with CP bar, but otherwise asymptomatic	1 (3)
Presence of oropharyngeal dysfunction	16 (52)
Presence of Zenker's diverticulum	7 (23)

UES: Upper esophageal sphincter; CP: Cricopharyngeal.

College Station, TX) on a per-patient basis. Descriptive statistics were calculated for all covariates and outcomes including *t* test, χ^2 test, and Fisher's exact test, where appropriate.

Procedural technique

Balloon dilatation of the upper esophageal sphincter was performed using two different techniques: Static and retrograde. With the traditional "static" technique, a through-the scope balloon dilation catheter (Boston Scientific Corporation, Natick, MA) is positioned across the upper esophageal sphincter under visual guidance without the use of a guidewire or fluoroscopy. The balloon is then sequentially inflated, holding the balloon in position for 30 to 60 s with each distention to a maximum diameter of 15 mm to 20 mm at the discretion of the endoscopist.

The retrograde approach across the UES is a newly described technique for the management of CPD. The actual technique has been used for mucosal disruption and treatment of esophageal rings, but has not been described in the management of CPD^[14]. In this approach, the TTS balloon is inflated to the maximal desired diameter under visual guidance in the proximal esophagus, distal to the UES. The fully distended balloon is then brought back to the tip of the endoscope. Both the endoscope and distended balloon are then withdrawn across the UES into the oropharynx as one unit, usually with moderate resistance.

In all cases, individuals were sedated for the procedure. After dilatation was performed, the UES and the surrounding structures were closely inspected for evidence of mucosal damage.

RESULTS

Over a consecutive three-year period 488 esophageal TTS balloon dilatations were performed at our institution, of which 31 patients had dilatation of the UES for CPD. The median age at time of UES dilatation was 63 years and 55% of the patients were male (Table 1). Indications

Table 2 Balloon dilatation procedural details *n* (%)

	Enrolled (<i>n</i> = 31)
Number of procedures per patient, median (range)	1 (1-3)
Type of initial dilatation	
Retrograde (brusque pull-back)	24 (77)
Static (sequential distention)	7 (23)
UES dilatation alone	20 (65)
Concurrent dilatation of the UES and other portions of the esophagus	11 (35)
Maximal diameter size, median (range)	20 mm (15-20 mm)
Total Number of complications	1 (3)
Serious complications requiring hospitalization	0

UES: Upper esophageal sphincter.

for UES dilatation are summarized in Table 1. Twenty-eight patients (90%) were experiencing dysphagia symptoms. In addition to CPD, 16 patients (52%) had evidence of concurrent oropharyngeal dysfunction and 7 patients (23%) were also found to have a Zenker's diverticulum.

Each individual underwent a median of 1 dilatation (range, 1-3), with 24 individuals (77%) receiving a retrograde approach (Table 2). The majority of individuals (26) underwent only 1 dilatation session. Four individuals underwent two dilatation sessions and one patient had three dilatation sessions. Eleven individuals had dilatation of other esophageal segments concurrently with UES dilatation and 20 patients had UES dilatation alone. Of those with multiple sites of esophageal dilatation, nine were for a Schatzki ring, one was for a peptic stricture and one was for subjective stenosis at the esophagogastric junction. The median maximal diameter for UES balloon dilatation was 20 mm, ranging from 15 to 20 mm. Three individuals were dilated with a 15 mm balloon, nine individuals were dilated with an 18 mm balloon, and nineteen individuals were dilated with a 20 mm balloon.

Follow-up was available for 24 of the 31 patients, 19 of whom underwent retrograde brusque technique. The median duration of follow-up was 2.5 mo (interquartile range: 1-10 mo), of whom 19 (79%) reported symptomatic improvement. Sixteen patients (84%) patients with the retrograde approach responded to dilatation, whereas 3 patients (60%) with the static dilatation approach responded to treatment. However, there was no statistically significant difference in symptom improvement between the two techniques (*P* = 0.5). Successful symptom resolution was also not significantly affected by dilator size, presence of oropharyngeal dysfunction, presence of a Zenker's diverticulum, age or gender (Table 3). Of those patients undergoing UES dilatation alone, follow-up was available for 15 patients, 12 of whom (80%) reported symptom improvement.

One patient developed uvular edema and a shallow ulcer after static dilatation of the UES that spontaneously resolved in the recovery room and did not require hospitalization. A second patient initially underwent dilatation of the GE junction that resulted in a

Table 3 Predictors of clinical response *n* (%)

Characteristic	Clinical response		<i>P</i> value
	Y (19)	N (5)	
Age, mean \pm SD	61.9 \pm 11.9	66.4 \pm 22.4	0.48
Sex, Male	10 (53)	2 (40)	0.68
Technique			
Retrograde	16	3	0.49
Static	3	2	
Maximal dilator size (mean \pm SD, mm)	19.2 \pm 1.4	19.6 \pm 0.9	0.25
Oropharyngeal dysfunction	11 (58)	2 (40)	0.68
Zenker's diverticulum	4 (21)	2 (40)	0.45

small mucosal tear that was adequately treated with placement of a single endoclip. During the same endoscopy, subsequent to endoclip placement, the patient underwent retrograde dilatation of the UES without complication. There were no adverse events associated with the retrograde brusque technique of the UES.

DISCUSSION

Oropharyngeal dysphagia can be associated with significant morbidity and treatments to date are imperfect and limited. Since first used for treatment of post-poliomyelitis dysphagia in 1951^[15], surgical myotomy has been the traditional approach for dysphagia related to cricopharyngeal prominence or dysfunction^[16-18]. However, efficacy remains controversial and this procedure is not without risk - particularly in elderly patients in whom cricopharyngeal bars are more common^[18-20]. Botulinum toxin injection has also been studied as a potential therapy and has been shown to be of benefit in several series^[21-23]. Reported complications have stemmed from diffusion of Botox to adjacent muscles leading to aspiration, worsened dysphagia, vocal cord paralysis and at least one recorded death^[24-26]. Moreover, the average duration of effect appears to be approximately 4 mo and waning efficacy may be observed with repeated therapy^[25].

Endoscopic dilatation of the upper esophageal sphincter poses an attractive therapeutic alternative for dysphagia related to CPD. Data, however, is limited to small case series - most of which contained less than 10 patients. The published data suggest that endoscopic dilatation may be a safe and effective option for carefully selected patients. A small series reported clinical improvement in 7 of 12 patients (58%) after dilatation with a Savary dilator (17 mm)^[8]. Another limited series reported higher rates of symptomatic improvement in 9 of 10 patients (90%) with similar dilatation techniques (18-20 mm)^[9]. Patel *et al*^[13] recently reported a larger experience with 31 patients undergoing Savary dilatation with 45 French to 60 French size dilators. In this study, 65% of patients had significant improvement for at least 6 mo using a functional outcome swallow score.

One study of 5 patients undergoing static balloon dilatation of the UES to a maximal diameter of 20 mm achieved 100% success rate^[10]. Another study reported

complete success in 6 patients undergoing dilatation of CP bars, but this study only included one patient with balloon dilatation to 20 mm and the five others underwent Savary dilatation^[12]. In these series and reports, there have been no recorded major complications. There has been one report of superficial mucosal injury after dilatation that was self-limited and did not require treatment or hospitalization^[10]. The recent systematic review on management of CPD reported comparable success rates of endoscopic dilation and myotomy; however, the authors comment that there were significantly fewer studies investigating endoscopic dilatation (6 studies involving 113 patients) and therefore the data were insufficient to make a strong recommendation on the role of endoscopic dilatation for CPD^[1].

Our series represents the largest published series to date looking at endoscopic balloon dilatation of the upper esophageal sphincter for dysphagia related to CPD. When compared to reported success rates for cricopharyngeal myotomy^[18,20], the results for endoscopic dilatation appear equivalent. Moreover, the safety profile of this approach appears to be excellent. In our series, the only reported complication was uvular edema and a shallow ulcer after balloon dilatation using a static technique in 1 patient that did not require admission and spontaneously improved over time. To our knowledge, there have been no perforations reported in the literature with this approach and certainly no fatalities.

At our institution, the preference has been to utilize endoscopic balloon dilatation via either a static or retrograde technique for CPD. The idea behind the static approach is to maximize radial forces while avoiding any sheering movements, whereas the concept for the retrograde approach is to combine radial and sheering forces with directed attention to the upper esophageal sphincter. As opposed to a Savary dilatation, the retrograde balloon technique may allow a more rapid increase in diameter and, with experience, a better subjective gauge of sphincter resistance. To our knowledge, this technique has not been previously reported in the literature for the management of CPD but has been used frequently at our institution for disruption of Schatzki rings, mucosal webs and upper esophageal sphincter dysfunction. While the safety of this approach has not been directly compared to conventional static dilatation, it has been our subjective opinion that the safety of these two approaches is equivalent. The one patient who developed a shallow ulcer in our series did so in the context of a static dilatation.

Traditionally, the presence of a Zenker's diverticulum has often been felt to represent a relative contraindication to endoscopic dilatation; however, mechanistically, these diverticula often arise in the context of elevated intrabolus pressure and/or upper esophageal sphincter dysfunction and for this reason may actually portend a better prognosis^[27]. Certainly in our series, response rates seemed equivalent between patients with and without a diverticulum and there did not appear to be any safety concerns. Likewise, oropharyngeal

dysfunction has been hypothesized to be a potential issue that may limit efficacy. However, this group may actually be more sensitive to minor mechanical alterations in outflow resistance and the presence of oropharyngeal dysfunction in our series did not affect or predict response.

Our study does have several limitations worth noting. To begin with, it is a retrospective evaluation and clinical response was determined subjectively through review of medical records. A prospective study with validated dysphagia questionnaires would have been ideal and this certainly is worth future consideration. Second, 11 of our patients had dilatation of other esophageal segments other than the upper esophageal sphincter and it is unclear if the symptom response was due to dilatation of the cricopharyngeus or the other segment of the esophagus. However, even without including these patients, this remains the largest published experience with endoscopic balloon dilatation for CPD. Third, the indications for dilatation in our series were heterogeneous and it is possible (and indeed likely) that certain subsets have significantly varied responses. For example, it is our subjective opinion that patients with inclusion body myositis likely have a greater response to dilatation; however, given the total number of patients in our study there is no way to statistically address that question. Finally, our median follow-up was 2.5 mo and given the underlying mechanisms of upper esophageal sphincter dysfunction a longer evaluation period would have been ideal.

In summary, UES dilatation with a TTS balloon by either static or retrograde technique is safe and effective for the treatment of dysphagia in the context of CP dysfunction. As suggested in prior smaller series, this appears to be a safe and effective approach. Our series, however, is the first to describe retrograde balloon dilatation of the UES. Given this data is tandem with the reported complications of surgical myotomy and Botulinum toxin injection, we suggest that endoscopic dilatation of the upper esophageal sphincter should be the first therapy offered for patients with oropharyngeal dysphagia in the context of upper esophageal sphincter dysfunction. In addition, our experience would suggest that balloon dilatation *via* a retrograde technique is at least as safe and effective as conventional methods with either Savary or static balloon dilatation.

COMMENTS

Background

Cricopharyngeal dysfunction (CPD) is associated with a variety of symptoms including globus sensation, oropharyngeal dysphagia, regurgitation, coughing, choking and recurrent aspiration. While a variety of treatment options have been proposed, endoscopic dilatation by pulling a fully inflated 15-20 mm balloon dilator in a retrograde manner across the upper esophageal sphincter appears to be safe and effective for the treatment of cricopharyngeal dysphagia.

Research frontiers

Optimal management of cricopharyngeal dysphagia is not clear. Endoscopic dilatation appears to be safe with immediate relief of symptoms. Several small

series have demonstrated benefit with endoscopic dilatation using a variety of techniques. Additional research into the durability of the procedure and objective parameters of relief are needed.

Innovations and breakthroughs

This represents the largest endoscopic experience for managing CPD. In this series, a novel dilatation technique of pulling a fully inflated 15-20 mm balloon dilator in a retrograde manner across the upper esophageal sphincter was safe and effective for the treatment of cricopharyngeal dysphagia.

Applications

The retrograde dilatation technique provides another method for effective dilatation and disruption of the upper esophageal sphincter complex to relieve symptoms associated with cricopharyngeal dysphagia. Many endoscopists are more comfortable with balloon dilatation and this technique may allow them to better treat CPD using this technique.

Terminology

CPD - refers to incoordination of the cricopharyngeal muscle either due to a primary functional disorder or as a result of an underlying neurological or medical condition.

Peer-review

This is a study assessing the efficacy of endoscopic balloon catheter dilatation for treatment of cricopharyngeal dysfunction. The authors retrospectively reviewed all UES dilatations performed during a three year period. Thirty-one patients were included although follow-up was only available for 24. A symptomatic improvement was confirmed for 80% of patients. The manuscript is well written and describes a large series of cases.

REFERENCES

- 1 **Kocdor P**, Siegel ER, Tulunay-Ugur OE. Cricopharyngeal dysfunction: A systematic review comparing outcomes of dilatation, botulinum toxin injection, and myotomy. *Laryngoscope* 2016; **126**: 135-141 [PMID: 26360122 DOI: 10.1002/lary.25447]
- 2 **Baredes S**, Shah CS, Kaufman R. The frequency of cricopharyngeal dysfunction on videofluoroscopic swallowing studies in patients with dysphagia. *Am J Otolaryngol* 1997; **18**: 185-189 [PMID: 9164621 DOI: 10.1016/S0196-0709(97)90080-6]
- 3 **Cook IJ**, Kahrilas PJ. AGA technical review on management of oropharyngeal dysphagia. *Gastroenterology* 1999; **116**: 455-478 [PMID: 9922328 DOI: 10.1016/S0016-5085(99)70144-7]
- 4 **Dantas RO**, Cook IJ, Dodds WJ, Kern MK, Lang IM, Brasseur JG. Biomechanics of cricopharyngeal bars. *Gastroenterology* 1990; **99**: 1269-1274 [PMID: 2210235]
- 5 **Ross ER**, Green R, Auslander MO, Biller HF. Cricopharyngeal myotomy: management of cervical dysphagia. *Otolaryngol Head Neck Surg* 1982; **90**: 434-441 [PMID: 6817273 DOI: 10.1177/019459988209000413]
- 6 **Herberhold C**, Walther EK. Endoscopic laser myotomy in cricopharyngeal achalasia. *Adv Otorhinolaryngol* 1995; **49**: 144-147 [PMID: 7653350 DOI: 10.1159/000424359]
- 7 **Lawson G**, Remacle M. Endoscopic cricopharyngeal myotomy: indications and technique. *Curr Opin Otolaryngol Head Neck Surg* 2006; **14**: 437-441 [PMID: 17099353 DOI: 10.1097/MOO.0b013e3280106314]
- 8 **Ali GN**, Wallace KL, Laundl TM, Hunt DR, deCarle DJ, Cook IJ. Predictors of outcome following cricopharyngeal disruption for pharyngeal dysphagia. *Dysphagia* 1997; **12**: 133-139 [PMID: 9190098 DOI: 10.1007/PL00009527]
- 9 **Hatlebakk JG**, Castell JA, Spiegel J, Paoletti V, Katz PO, Castell DO. Dilatation therapy for dysphagia in patients with upper esophageal sphincter dysfunction--manometric and symptomatic response. *Dis Esophagus* 1998; **11**: 254-259 [PMID: 10071809]
- 10 **Solt J**, Bajor J, Moizs M, Grexa E, Horváth PO. Primary cricopharyngeal dysfunction: treatment with balloon catheter dilatation. *Gastrointest Endosc* 2001; **54**: 767-771 [PMID: 11726859]

- DOI: 10.1067/mge.2001.118442]
- 11 **Zepeda-Gómez S**, Montaña Loza A, Valdovinos F, Schmulson M, Valdovinos MA. Endoscopic balloon catheter dilation for treatment of primary cricopharyngeal dysfunction. *Dig Dis Sci* 2004; **49**: 1612-1614 [PMID: 15573914]
 - 12 **Wang AY**, Kadkade R, Kahrilas PJ, Hirano I. Effectiveness of esophageal dilation for symptomatic cricopharyngeal bar. *Gastrointest Endosc* 2005; **61**: 148-152 [PMID: 15672078 DOI: 10.1016/S0016-5107(04)02447-2]
 - 13 **Patel BJ**, Mathur AK, Dehom S, Jackson CS. Savary dilation is a safe and effective long-term means of treatment of symptomatic cricopharyngeal bar: a single-center experience. *J Clin Gastroenterol* 2014; **48**: 500-504 [PMID: 24231933 DOI: 10.1097/MCG.0000000000000026]
 - 14 **Chung RS**. Retrograde dilation of esophageal strictures with balloon dilators. *Surg Endosc* 1991; **5**: 68-69 [PMID: 1948616 DOI: 10.1007/BF00316839]
 - 15 **Kaplan S**. Paralysis of deglutition, a post-poliomyelitis complication treated by section of the cricopharyngeus muscle. *Ann Surg* 1951; **133**: 572-573 [PMID: 14819998 DOI: 10.1097/0000658-195104000-00021]
 - 16 **Berg HM**, Jacobs JB, Persky MS, Cohen NL. Cricopharyngeal myotomy: a review of surgical results in patients with cricopharyngeal achalasia of neurogenic origin. *Laryngoscope* 1985; **95**: 1337-1340 [PMID: 4058211 DOI: 10.1288/00005537-198511000-00008]
 - 17 **Bonavina L**, Khan NA, DeMeester TR. Pharyngoesophageal dysfunctions. The role of cricopharyngeal myotomy. *Arch Surg* 1985; **120**: 541-549 [PMID: 3921004 DOI: 10.1001/archsurg.1985.01390290023004]
 - 18 **Kelly JH**. Management of upper esophageal sphincter disorders: indications and complications of myotomy. *Am J Med* 2000; **108** Suppl 4a: 43S-46S [PMID: 10718451 DOI: 10.1016/S0002-9343(99)00334-4]
 - 19 **Leonard R**, Kendall K, McKenzie S. UES opening and cricopharyngeal bar in nondysphagic elderly and nonelderly adults. *Dysphagia* 2004; **19**: 182-191 [PMID: 15383948 DOI: 10.1007/s00455-004-0005-6]
 - 20 **Buchholz DW**. Cricopharyngeal myotomy may be effective treatment for selected patients with neurogenic oropharyngeal dysphagia. *Dysphagia* 1995; **10**: 255-258 [PMID: 7493506 DOI: 10.1007/BF00431418]
 - 21 **Murry T**, Wasserman T, Carrau RL, Castillo B. Injection of botulinum toxin A for the treatment of dysfunction of the upper esophageal sphincter. *Am J Otolaryngol* 2005; **26**: 157-162 [PMID: 15858769 DOI: 10.1016/j.amjoto.2004.11.010]
 - 22 **Kim DY**, Park CI, Ohn SH, Moon JY, Chang WH, Park SW. Botulinum toxin type A for poststroke cricopharyngeal muscle dysfunction. *Arch Phys Med Rehabil* 2006; **87**: 1346-1351 [PMID: 17023244 DOI: 10.1016/j.apmr.2006.06.018]
 - 23 **Alfonsi E**, Merlo IM, Ponzio M, Montomoli C, Tassorelli C, Biancardi C, Lozza A, Martignoni E. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. *J Neurol Neurosurg Psychiatry* 2010; **81**: 54-60 [PMID: 19762326 DOI: 10.1136/jnnp.2009.174698]
 - 24 **Zaninotto G**, Marchese Ragona R, Briani C, Costantini M, Rizzetto C, Portale G, Zanetti L, Masiero S, Costantino M, Nicoletti L, Polidoro A, Feltrin G, Angelini C, Ancona E, Guidolin D, Parenti AR. The role of botulinum toxin injection and upper esophageal sphincter myotomy in treating oropharyngeal dysphagia. *J Gastrointest Surg* 2004; **8**: 997-1006 [PMID: 15585387 DOI: 10.1016/j.gassur.2004.09.037]
 - 25 **Moerman MB**. Cricopharyngeal Botox injection: indications and technique. *Curr Opin Otolaryngol Head Neck Surg* 2006; **14**: 431-436 [PMID: 17099352 DOI: 10.1097/MOO.0b013e328010b85b]
 - 26 **Cook IJ**. Treatment of Oropharyngeal Dysphagia. *Curr Treat Options Gastroenterol* 2003; **6**: 273-281 [PMID: 12846936 DOI: 10.1007/s11938-003-0019-4]
 - 27 **Ferreira LE**, Simmons DT, Baron TH. Zenker's diverticula: pathophysiology, clinical presentation, and flexible endoscopic management. *Dis Esophagus* 2008; **21**: 1-8 [PMID: 18197932 DOI: 10.1111/j.1442-2050.2007.00795.x]

P- Reviewer: Bustamante-Balén N, Goenka MK, Ljubicic N, Muguruma N **S- Editor:** Kong JX **L- Editor:** A **E- Editor:** Wu HL





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.f6publishing.com>

